Clinical Trial: HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Liver Cancer
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of Hepatic Arterial inFusion Chemotherapy Sequential transaRterial Embolization cOmbined With leNvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma (FRONT Trial)
Brief Summary:
Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
Read more